We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin
News

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin
News

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announced that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,884,072- entitled, "Prolactin induced increase in neural stem cell number." The claims contained within this issued patent cover methods of using an effective amount of prolactin to increase stem cell numbers in mammals suspected of having neurological diseases.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "This issued patent and other anticipated patents for the use of prolactin greatly assist the protection and capture of shareholder value for this therapeutic program. The important exclusivity that has been granted for the use of prolactin today combined with ever increasing scientific evidence supporting the use of prolactin builds upon the wealth of intellectual property that SCT possesses. We look forward to the continued advancement of this program in the future."
Advertisement